Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 28;5(7):690-718.
doi: 10.3390/ph5070690.

Chemotherapeutic interventions against tuberculosis

Neeraj Shakya  1 , Gaurav Garg, Babita Agrawal, Rakesh Kumar
Affiliations

Chemotherapeutic interventions against tuberculosis

Neeraj Shakya et al. Pharmaceuticals (Basel). .

Abstract

Tuberculosis is the second leading cause of infectious deaths globally. Many effective conventional antimycobacterial drugs have been available, however, emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has overshadowed the effectiveness of the current first and second line drugs. Further, currently available agents are complicated by serious side effects, drug interactions and long-term administration. This has prompted urgent research efforts in the discovery and development of new anti-tuberculosis agent(s). Several families of compounds are currently being explored for the treatment of tuberculosis. This review article presents an account of the existing chemotherapeutics and highlights the therapeutic potential of emerging molecules that are at different stages of development for the management of tuberculosis disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
First line anti-tuberculosis drugs.
Figure 2
Figure 2
Pyrimidine nucleosides as anti-tuberculosis agents.
Figure 3
Figure 3
Acyclic pyrimidine nucleosides as anti-tuberculosis agents.
Figure 4
Figure 4
Some recent pyrimidine nucleosides as anti-tuberculosis agents.
Figure 5
Figure 5
Purine nucleosides as anti-tuberculosis agents.
Figure 6
Figure 6
Carbohydrate derivatives as anti-tuberculosis agents.
Figure 7
Figure 7
Fluoroquinolones as anti-tuberculosis agents.
Figure 8
Figure 8
Quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-tuberculosis agents.
Figure 9
Figure 9
1,4-di-N-oxide-3-phenylquinoxalines as anti-tuberculosis agents.
Figure 10
Figure 10
Some other quinoline derivatives as anti-tuberculosis agents.
Figure 11
Figure 11
Pyrimidine and Purine analogs as anti-tuberculosis agents.
Figure 12
Figure 12
Azole analogs as anti-tuberculosis agents.
Figure 13
Figure 13
N-Aryl-C-nitroazoles as anti-tuberculosis agents.
Figure 14
Figure 14
Azines as anti-tuberculosis agents.
Figure 15
Figure 15
INH analogs as anti-tuberculosis agents.
Figure 16
Figure 16
Artemisinin analog as anti-tuberculosis agents.
Figure 17
Figure 17
Macrolide as anti-tuberculosis agents.
Figure 18
Figure 18
Structure of thiolactomycin.
Figure 19
Figure 19
Structure of CPZEN-45.
Figure 20
Figure 20
Structure of DC-159a.
Figure 21
Figure 21
Structure of SQ609.
Figure 22
Figure 22
Structure of SQ-641.
Figure 23
Figure 23
Structure of BTZ-043.
Figure 24
Figure 24
Structure of tryptanthrin.
Figure 25
Figure 25
Structure of PNU-100480.
Figure 26
Figure 26
Structure of LL3858.
Figure 27
Figure 27
Structure of SQ109.
Figure 28
Figure 28
Structure of PA-824.
Figure 29
Figure 29
Structure of OPC-67683.
Figure 30
Figure 30
Structure of TMC-207.
Figure 31
Figure 31
Structure of linezolid.
Figure 32
Figure 32
Structure of rifapentine.
Figure 33
Figure 33
Structures of moxifloxacin and gatifloxacin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organisation (WHO) WHO Global Task Force outlines measures to combat XDR-TB worldwide (17 October 2006) [(accessed on 4 April 2012)]. Available online: http://www.who.int/mediacentre/news/notes/2006/np29/en/index.html/
    1. Rowland K. Totally drug-resistant TB emerges in India, Nature News. [(accessed on 9 June 2012)]. Available online: http://www.nature.com/news/totally-drug-resistant-tb-emerges-in-india-1....
    1. Kaufmann S.H.E. Tuberculosis vaccines—A new kid on the block. Nat. Med. 2011;17:159–160. doi: 10.1038/nm0211-159. - DOI - PubMed
    1. Nau R., Prange H.W., Menck S., Kolenda H., Visser K., Seydel J.K. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J. Antimicrob. Chemother. 1992;29:719–724. doi: 10.1093/jac/29.6.719. - DOI - PubMed
    1. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des. 2006;12:4047–4070. doi: 10.2174/138161206778743646. - DOI - PubMed

LinkOut - more resources